What Human Longevity Found After Screening 10,000 “Healthy” People
In a Nutshell
Human Longevity's screening of 10,000+ "healthy" people revealed ~2% had brain aneurysms, ~2% had undetected tumors, and many had severe coronary artery disease (calcium scores up to 1,500 with 80%+ blockages). Genome accounts for 40-55% of lifespan and heart attack risk, enabling polygenic risk scores to identify high-risk individuals in their 40s who can reduce risk back to normal through LDL, Lp(a), and CRP reduction. Current population-based medicine fails to detect these conditions because 2% prevalence isn't cost-effective at scale, despite 100% risk for affected individuals.
These notes were generated by AI and may contain inaccuracies.
Human Longevity has screened over 10,000 people who declared themselves as healthy. The landmark publication in Proceedings of the National Academy of Sciences from 2000 summarized initial findings from 1,200 clients and these findings continue to hold true after screening more than 10,000 individuals.
Approximately 1.7-2% of people screened have a brain aneurysm. This represents a significantly higher prevalence than commonly expected. For example, statistically speaking, approximately 1.7-2 people out of every 100 on the street would have an aneurysm. This condition represents a ticking time bomb if left undiagnosed, as evidenced by the case of a dinner companion whose cousin died of a brain aneurysm in their 30s.
Nearly 2% of people screened have a small tumor growing in their body. Additionally, certain individuals have coronary artery calcium scores as high as 1,500, and subsequent CTA imaging reveals arteries that are already 80% blocked. One documented case involved a person with 80%+ arterial blockage who was warned to see a cardiologist immediately. The individual experienced a heart attack between the exam and their scheduled appointment but survived because they were prepared and called 911.
Screening reveals carriers of genes including BRCA1, BRCA2, and Lynch syndrome genes, representing various genetic predispositions. The data shows that for heart attack risk, approximately 10% of any given group of 100 people are at high risk for coronary artery disease.
The screening approach reveals that while rare diseases individually affect less than 1% of the population, when combined they represent the most common group of diseases. This illustrates how individual small risks compound into significant health and longevity risks.
A client with compound heterozygotes for cystic fibrosis presented with chronic nasal infections and food digestion problems. Previous functional medicine treatment focused on cortisol and allergy management. CT and MRI imaging revealed the characteristic tree phenotype in the lungs, confirming a mild form of cystic fibrosis rather than allergies. Without precision imaging, this condition could remain undiagnosed for 20-30 years.
A 2026 Science paper from the Weizmann Institute indicates that genome accounts for 50-55% of lifespan importance, significantly higher than the historical estimate of 15%. This revised understanding emerged after accounting for extrinsic factors like accidents, pneumonia, and smallpox.
Human Longevity's approach is characterized as conducting a precision medicine Framingham study. The longer the dataset, the more accurate predictions become. Simple mutations like BRCA1 and BRCA2 have extensive outcome data accumulated over 30 years by companies like Myriad Genetics, enabling increasingly accurate risk calculations for breast and ovarian cancer.
A JACC paper based on 200,000 UK Biobank participants followed for 12 years demonstrated that 6,000 people experienced heart attack or coronary artery disease events. The study used four markers: a polygenic risk score based on 1.2 million SNPs, high-sensitivity CRP, LDL, and Lp(a). Genome was found to account for approximately 40-50% of heart attack prediction power.
The polygenic risk score creates a bell curve distribution where some individuals at the extreme low-risk end can smoke and drink without experiencing heart attacks. Conversely, individuals in the top 10% risk category are significantly more prone to heart attack or coronary artery disease. The addition of high-sensitivity CRP, LDL, and Lp(a) dramatically increases predictive value.
The algorithm enables prediction for younger populations in their 40s, identifying those in the top 10% risk category. Critically, individuals with high genetic risk can reduce their risk back to normal levels by lowering LDL, Lp(a), and high-sensitivity CRP through lifestyle changes and medications such as statins.
Human Longevity validated the UK Biobank algorithm using calcium scores as a surrogate marker for coronary artery blockage in their cohort of over 10,000 people. The UK Biobank data proved accurate for Caucasians but required modification for Asian, Indian, and African American populations due to the predominantly Caucasian composition of the original dataset.
For individuals with calcium scores above 100, CT angiograms using Cleerly technology are recommended to assess soft plaque and identify potentially fatal lesions. Human Longevity estimates they can reduce heart attack risk by 80% in high-risk groups, particularly those in their 40s.
Family history may not reveal cardiovascular disease even when genomic risk exists, as genetic inheritance represents a random combination from parents. A personal example demonstrates this: the speaker's father had hypertension, mother had diabetes, sister inherited hypertension, and the speaker inherited pre-diabetes, despite having normal blood pressure.
Human Longevity has developed polygenic risk scores to predict whether LDL levels will be high, with validation against actual LDL measurements from all clients. The system accounts for racial differences in these predictions.
Future genomic analysis should be agnostic to self-reported race and ethnicity, as increasing interracial populations make traditional race categories less meaningful. Genome sequencing itself can determine ancestry.
The comprehensive screening process, developed 13 years ago, involves 5-6 hours at the clinic including genome sequencing, deep blood panels, whole body MRI, calcium score via low-dose CT, cardiac echo, and DEXA scan. This generates 150-200 GB of data per person. Each client receives a concierge physician for guidance through the longevity care model.
Physician involvement is critical because laypeople may not understand the significance of findings such as elevated Lp(a) levels. Many physicians historically did not test for Lp(a), despite it being one of the biggest risk factors for future heart attack. Medical school training typically does not cover Lp(a) testing.
A woman in her 70s had a polygenic risk score for IBD at the 98th percentile. Despite negative Grail and Cologuard liquid biopsy tests followed by negative colonoscopy, further investigation revealed stage 3 appendix cancer. Current US guidelines do not include appendix cancer screening. The case demonstrates the value of combining polygenic risk scores, liquid biopsy, and thorough clinical investigation.
Current population medicine is based on 50-year-old cost-benefit analyses derived from population-level risk assessments. This approach misses conditions affecting 2% of the population because population-level screening is not cost-effective, even though such conditions represent 100% risk for affected individuals. Advanced screening capabilities that were historically expensive are now becoming accessible for a few hundred dollars.
The current period represents an evolution and renaissance of medical innovation where previously impossible interventions are becoming feasible, supporting a more optimistic outlook on health possibilities.
Keep Hillary Lin, MD in your library
Save the videos and channels worth coming back to, and find them again in one place.
